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Invasive fungal infection (IFI) is a common complication in children with hematological malignancies. While Candida species, Aspergillus species, and Cryptococcus neoformans 
are responsible for the majority of IFIs, mucormycosis is the 
second most common invasive mold infection [1]. Mucormycosis 
(also called zygomycosis) is the name for the group of diseases 
caused by the fungi of the order Mucorales of zygomycetes class. 
It is considered to be an uncommon opportunistic infection that 
usually affects immunocompromised patients such as those 
suffering from hematological malignancies, patients undergoing 
bone marrow transplantation, and kidney transplantation.
Rhinocerebral mucor infections are commonly described in 
the literature. Although renal involvement is not so uncommon 
in disseminated mucormycosis, isolated renal involvement 
is extremely rare with only case reports being reported. 
Mucormycosis responds poorly to antifungals alone and 
frequently requires resection of the affected organ. Unlike other 
common fungal infections like Candida, mucormycosis has a 
poor prognosis, especially in immunocompromised patients. 
Here, we describe a child with acute lymphoblastic leukemia 
(ALL) who developed Mucor pyelonephritis with renal abscess 
and was successfully treated with antifungals and nephrectomy, 
followed by the review of literature.
CASE REPORT
A 7-year-old Indian girl presented with complaints of easy 
bruising for 1 week. She was diagnosed with Pre-B ALL after 
bone marrow studies. She was started on treatment as per Berlin-
Frankfurt-Munster (BFM) ALL-90 protocol after securing a 
central line. During induction chemotherapy, she developed 
febrile neutropenia. Two sets of blood cultures were sterile. 
Urine culture grew Escherichia coli. She was treated with broad-
spectrum antibiotics. As fever persisted, fungal workup was done.
Computed tomography (CT) of the chest and echocardiogram 
was normal. Invasive fungal markers like serum galactomannan 
were done to rule out other fungal invasive infections and 
were found negative. Ultrasound (USG) of the abdomen was 
done which showed heterogeneous hypo-echoic echogenicity 
with no demonstrable vascularity at the upper pole of the right 
kidney - suggestive of infarction or infectious etiology. CT 
abdomen showed well-defined non-enhancing, low attenuating 
focus in the upper and mid pole of the right kidney, indicating 
evolving abscess with pyelonephritis (Fig. 1). It also revealed a 
non-obstructing cast with central calcification in the right renal 
pelvis.
Subsequently, she underwent fine-needle aspiration cytology, 
which was consistent with fungal infection but speciation was not 
possible. Repeated blood cultures were done to rule out fungemia 
in the bloodstream, which was negative. In the absence of 
fungemia, and the fungal infection being localized to the kidney, we 
continued to use the central line with standard aseptic precautions. 
Antifungal was escalated to amphotericin B. Follow-up USG 
abdomen showed interval development of cystic changes at the 
upper pole of right kidney and right hydroureteronephrosis with 
echogenic content - fungal ball. CT abdomen showed interval 
development aneurysmal dilation of the upper interpolar hilar 
division of the right renal artery - likely representing mycotic 
aneurysm. CT chest was normal.
In view of progressive fungal infection despite antifungals, 
the right radical nephrectomy was done. Histopathological 
examination showed broad non-septate, pleomorphic hyphae 
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predominantly branching at right angles, which are characteristic 
features of mucormycosis (Fig. 2). It also showed dense 
lymphoplasmacytic infiltrate with granulomatous reaction and 
giant cell reaction. Acid-fast bacilli (AFB) stain for tuberculosis 
was negative. Ureter and renal vessels were unremarkable. 
Antifungals were given for 2 weeks postoperatively. Post-
operative recovery was uneventful. Chemotherapy was continued, 
and she finished maintenance chemotherapy about 2 years back. 
Presently, she is going to school and doing well.
DISCUSSION
IFI is commonly encountered in children receiving chemotherapy. 
The incidence of IFI has been reported from 14% to 24 % by 
various investigators [2,3]. Most common fungal pathogens are 
candidiasis and aspergillosis. The incidence of mucormycosis 
is five- to ten-fold less than the other fungal infections [1]. In a 
review by Pagano et al., two-thirds of IFI cases were attributable 
to molds and the rest of yeasts. Out of the infections caused by 
molds, zygomycetes accounted for only 4% of cases [4]. Rhizopus, 
Mucor, and Lichtheimia (formerly Absidia) are the most common 
genera that cause mucormycosis, accounting for 70–80% of all 
cases, whereas Cunninghamella, Apophysomyces, Saksenaea, 
Rhizomucor, Cokeromyces, Actinomucor, and Syncephalastrum 
are responsible for <1–5% of reported cases [5].
Mucormycosis affects all age groups from neonates to geriatric 
patients. The risk factors for mucormycosis are hematological 
malignancies, trauma, diabetes mellitus, malnutrition, severe burns, 
immunosuppressive therapy, etc. The major underlying conditions 
responsible for mucormycosis, as reported by “The global fungal 
infection registry” are: Malignancy (63%), diabetes (17%), and solid 
organ transplantation (10%) [5]. The transmission of mucormycosis 
is by inhalation of spores, through the gastrointestinal route or by 
implantation of spores at the sites of trauma [6]. The risk factors in 
our child were the malignancy and immunosuppressive therapy and 
the mode of transmission was probably inhalation. Angioinvasion 
is one of the characteristics of mucormycosis, which leads to vessel 
thrombosis, tissue necrosis, and disseminated disease [5].
Data on mucormycosis in immunocompromised children are 
limited. Rhinocerebral mucormycosis is the most common form of 
mucormycosis. Other sites such as the lungs, intestinal tract, and 
skin can also be affected, although isolated kidney involvement 
is rarely described [6]. Similarly, reports of nasal sinuses 
mucormycosis, intraoral mucormycosis, muscular mucormycosis, 
and the hepatic mucormycosis have been described by various 
investigators. In a review by Pagano et al., in patients with 
hematologic malignancies, lung (64%) was the most frequent site 
of mucormycosis followed by orbito-sinus-facial structures (24%), 
while cerebral involvement and disseminated infection were 
observed in only 19% and 8% of the cases, respectively [4]. Dabritz 
et al. reported 12 pediatric cases of mucormycosis involving soft 
tissues, lungs, and rhino-cerebrum [1]. Very few reports describe 
an isolated renal involvement. Similar to our child, Keishin et al. 
described a 14-year-old girl with ALL who developed isolated renal 
abscess due to mucormycosis and was treated with antifungals 
and nephrectomy [6]. Yu et al. described another case of isolated 
renal zygomycosis due to Rhizopus oryzae, but in a patient with 
systemic lupus erythematosus on steroids [7].
Diagnosis of mucormycosis depends on the identification 
of morphological features of the etiologic agent. Characteristic 
features include invasion of the vessels walls and presence of 
fungi in the glomeruli, tubules, and interstitium [6]. Diagnosis of 
mucormycosis is difficult as bacteria are frequently isolated from 
the tissue, which may dissuade the clinician from suspecting a 
concomitant IFI [1]. Katragkou et al. also attributed the difficulty 
in diagnosis to tissue handling. Aggressive tissue grinding or 
homogenization may destroy the hyphae. Furthermore, antifungal 
therapy commenced before the biopsy can lead to atypical 
morphological features, thereby posing a diagnostic dilemma [5]. 
Because of the frequent presence of tissue necrosis, macrophage 
infiltration, langerhans cell accumulation and granuloma formation, 
tuberculosis is one of the differential diagnosis. The AFB stain on 
our child was negative thus excluding tuberculosis as the causative 
agent. Other differentials are renal tumors, infarction, abscesses, 
and angioinvasive pathogens such as Aspergillus spp., Fusarium 
spp., Scedosporium spp., and Pseudomonas aeruginosa [5,6].
Figure 1: Computed tomography of the abdomen showing lesion in 
the upper pole of the right kidney
Figure 2: Histopathological examination is showing broad non-
septate, pleomorphic hyphae predominantly branching at right 
angles
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Iron plays a central role in the pathogenesis of mucormycosis 
and Francesco et al. have suggested the use of iron chelators as 
adjunctive therapy along with avoidance of iron supplementation 
and blood transfusion. They also reported a case of recurrent 
rhino-cerebral mucormycosis treated with antifungals, surgery, 
and long-term posaconazole [1]. In their review, they report 
that diabetic patients with rhino-oculo-cerebral mucormycosis 
receiving liposomal amphotericin and caspofungin had a survival 
advantage over those receiving a single drug [1]. Cofre et al. also 
reported that caspofungin and amphotericin B were synergistic 
in vitro [8]. There are also case reports advocating the use of 
hyperbaric oxygen in the treatment of mucormycosis [1].
The time of initiation of antifungal is extremely important 
as Chamilos et al. reported a two-fold increase in mortality 
resulting from delayed amphotericin-B (AMB) based therapy 
(83% vs. 49%) [5]. In another study, patients with hematologic 
malignancies and zygomycosis in whom AMB-based therapy 
against zygomycosis was delayed had higher mortality at 12 weeks 
than patients who had received treatment early [9]. Although 
surgery forms the cornerstone of treatment in mucormycosis, 
Mutchnick et al. have reported a successful outcome in invasive 
orbital and intracranial rhino-mucormycosis without orbital 
exenteration or cerebral debridement [10].
Mucormycosis has a grave prognosis, and majority of 
patients still die within 12 weeks of diagnosis if not managed 
properly [1]. In a review by Pagano et al., the highest IFI-
attributable mortality rate was associated with zygomycosis 
(64%), which was followed, by fusariosis (53%), aspergillosis 
(42%), and candidemia (33%) [4]. Katragkou et al. also opined 
that the invasive nature of the disease leads to overall mortality 
exceeding 50% [5]. Hence, early diagnosis and treatment are of 
utmost importance in the treatment of mucormycosis.
CONCLUSION
Mucormycosis as a cause of IFI is rarely encountered in children 
with ALL with isolated renal involvement being even rarer. 
Due to the difficulties encountered in diagnosis, a high level of 
suspicion is required to diagnose mucormycosis. Despite the 
advent of newer antifungal agents, the prognosis remains poor. 
Our case demonstrates that aggressive treatment with antifungals 
and surgery is essential to improve outcome.
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